Want to see REVB full AI Analyst Report?
Revelation Biosciences (REVB) Stock Forecast & Price Target
REVB Analyst Ratings
REVB Stock 12 Month Forecast
Average Price Target
$16.00▲(295.06% Upside)Detailed List of Analyst Forecasts
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Jonathan Aschoff | Roth MKM | $16 | buy | 295.06%Upside | Reiterated | 08/07/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Jonathan Aschoff | 08/07/26 | $16 | buy | 295.06%Upside | Reiterated | Roth MKM |
Best Analysts Covering Revelation Biosciences
Copying Jonathan Aschoff's trades and holding each position for 3 Months would result in 7.14% of your transactions generating a profit, with an average return of -41.19% per trade.
Copying Jonathan Aschoff's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -81.31% per trade.
Copying Jonathan Aschoff's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -84.17% per trade.
REVB Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 1 | 1 | 1 | 1 | 1 |
In the current month, REVB has received 1 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. REVB average Analyst price target in the past 3 months is 16.00.
REVB Financial Forecast
REVB Earnings Forecast
Next quarter’s earnings estimate for REVB is -$6.16 with a range of -$6.58 to -$5.74. The previous quarter’s EPS was -$6.09. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
REVB Sales Forecast
Next quarter’s sales forecast for REVB is $0 with a range of $0 to $0. The previous quarter’s sales results were $0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
